Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fexofenadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | DRD3 | P35462 | 3/20 | 0.96 |
| ▸ | HTR2A | P28223 | 2/20 | 0.96 |
| ▸ | HTR2B | P41595 | 2/20 | 0.96 |
| ▸ | BLM | P54132 | 2/20 | 0.96 |
| ▸ | CNR1 | P21554 | 1/20 | 0.96 |
| ▸ | APEX1 | P27695 | 1/20 | 0.96 |
| ▸ | PDE4A | P27815 | 1/20 | 0.96 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.96 |
| ▸ | DRD2 | P14416 | 2/20 | 0.94 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.94 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.94 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.77 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.77 |
| ▸ | GMNN | O75496 | 1/20 | 0.77 |
| ▸ | USP2 | O75604 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fexofenadine SCHEMBL1561082 | 0.98 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL4900 | 0.98 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL7104316 | 0.98 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL3178320 | 0.98 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL4901 | 0.98 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1972366 | 0.98 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL16652202 | 0.97 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1395675 | 0.97 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL16652201 | 0.97 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL20531399 | 0.97 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| EP-3482753-B1 | COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2021-01-27 | — | — | EP | disclosed |
| US-20200222409-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2020-07-16 | — | — | US | disclosed |
| US-10617689-B2 | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | PHARNEXT (FR) | 2020-04-14 | — | — | US | disclosed |
| US-10596160-B2 | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | PHARNEXT (FR) | 2020-03-24 | — | — | US | disclosed |
| EP-2914252-B1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2019-09-04 | — | — | EP | disclosed |
| EP-3482753-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | Pharnext (FR) | 2019-05-15 | — | — | EP | disclosed |
| US-20190008841-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2019-01-10 | — | — | US | disclosed |
| US-10092554-B2 | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | PHARNEXT (FR) | 2018-10-09 | — | — | US | disclosed |
| EP-3137065-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | Pharnext (FR) | 2017-03-08 | — | — | EP | disclosed |
| US-20170049777-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | PHARNEXT (FR) | 2017-02-23 | — | — | US | disclosed |
| US-20160235693-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2016-08-18 | — | — | US | disclosed |
| CN-103610645-B | A kind of pharmaceutical composition of fexofenadine hydrochloride and preparation method | ZHEJIANG WANSHENG PHARMACEUTICAL Co.,Ltd. (CN) | 2016-05-11 | — | — | CN | disclosed |
| WO-2015165948-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | PHARNEXT (FR) | 2015-11-05 | — | — | WO | disclosed |
| US-20150231123-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2015-08-20 | — | — | US | disclosed |
| CN-103610645-A | Pharmaceutical composition with fexofenadine hydrochloride and preparation method of pharmaceutical composition | ZHEJIANG WANMA PHARMACEUTICAL CO LTD | 2014-03-05 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | HRH1 4682/4885KCNH2 4822/4885LMNA 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.